natgillin/translations-raw huggingface dataset:
Incidence of infectious episodes: The overall incidence and profile of viral, bacterial and fungal infections among patients treated with basiliximab or placebo in combination with dual and triple immunosuppressive therapy was comparable between the groups. 
Incidenca okužb: Celotna incidenca in profil virusnih, bakterijskih in glivičnih okužb pri bolnikih, ki so bili zdravljeni z baziliksimabom ali s placebom v kombinaciji z dvotirnim ali tritirnim imunosupresivnim zdravljenjem, je bila primerljiva med obema skupinama.
Immunosuppressants reduce the body's response to anything that it sees as “foreign” - which includes transplanted organs. 
Zdravila za zaviranje imunske odzivnosti zmanjšajo odgovor organizma na snovi, ki jih telo spozna za ”tujek” - to so med drugim tudi presajeni organi.
2.5 ml of the sterile water is used to dissolve the powder before it is given to you. 
2,5 ml sterilne vode se uporabi, da se pred uporabo raztopi prašek.
However, based on the IgG1 nature of basiliximab, excretion into milk should be expected. 
Ker pa je baziliksimab IgG1, lahko pričakujemo njegovo izločanje v mleko.
You will be given other medicines to help protect your new kidney during this time, such as ciclosporin and corticosteroids and after you leave hospital. 
Prejeli boste še druga zdravila, kot so ciklosporin in kortikosteroidi, ki bodo pomagala obvarovati vašo novo ledvico v tem časovnem obdobju in tudi po zapustitvi bolnišnice.
Simulect belongs to a group of medicines called immunosuppressants. 
Simulect spada v vrsto zdravil, ki se imenujejo zdravila za zaviranje imunske odzivnosti (imunosupresivi).
The incidence of acute rejection episode was substantially lower in patients receiving basiliximab and a triple drug immunosuppressive regimen. 
Pogostost akutnih zavrnitvenih reakcij je bila bistveno manjša pri bolnikih, ki so dobivali baziliksimab in imunosupresivno shemo treh zdravil.
There are limited data available on the use of Simulect in the elderly, but there is no evidence that elderly patients require a different dosage from younger adult patients. 
Glede zdravljenja starejših z zdravilom Simulect je na voljo malo podatkov, vendar ni dokazov, ki bi narekovali pri starejših bolnikih drugačne odmerke kot pri mlajših odraslih bolnikih.
The incidence of CMV infections was similar in both groups (14.6% vs. 17.3%), following either dual or triple therapy regimen (see section 4.4). 
Incidenca okužb s citomegalovirusom (CMV) je bila podobna v obeh skupinah (14,6 % v primerjavi s 17,3 %) tako po dvotirnem kot po tritirnem zdravljenju (glejte poglavje 4.4).
Incidence of adverse events: In the above four placebo-controlled trials, the pattern of adverse events in 590 patients treated with the recommended dose of basiliximab was comparable to that observed in 595 patients treated with placebo. 
Incidenca neželenih učinkov: V zgoraj navedenih štirih raziskavah, kontroliranih s placebom, je bil vzorec neželenih učinkov pri 590 bolnikih, zdravljenih s priporočenim odmerkom baziliksimaba, primerljiv z vzorcem, opaženim pri 595 bolnikih, ki so dobili placebo.
The primary objective of the study was to demonstrate superiority of this combination versus treatment with ciclosporin for microemulsion, mycophenolate mofetil and steroids in the prevention of acute rejections. 
Primarni cilj študije je bil dokazati prednosti te kombinacije v primerjavi z zdravljenjem s ciklosporinom v mikroemulziji, z mofetilmikofenolatom in s steroidi pri preprečevanju akutne zavrnitve.
You should also tell your doctor if you are breast-feeding. 
Zdravniku morate prav tako povedati, če dojite.
Vaccination 
Cepljenje
In several small clinical trials in heart transplant recipients, serious cardiac adverse events such as cardiac arrest (2.2%), atrial flutter (1.9%) and palpitations (1.4%) have been reported more frequently with Simulect than with other induction agents. 
V nekaj manjših kliničnih študijah presaditve srca so pri prejemnikih o resnih srčnih neželenih dogodkih, kot so zastoj srca (2,2 %), atrijska undulacija (1,9 %) in palpitacije (1,4 %), poročali bolj pogosto pri uporabi zdravila Simulect kot pri uporabi katerega od drugih uvodnih (indukcijskih) zdravil.
Basiliximab has potentially hazardous immunosuppressive effects with respect to the course of gestation and the suckling neonate exposed to basiliximab in breast milk. 
Baziliksimab ima možne nevarne imunosupresivne učinke na potek nosečnosti in na dojenčka, ki je izpostavljen baziliksimabu v materinem mleku.
In the 39-week study, the highest dose resulted in approximately 1,000 times the systemic exposure (AUC) observed in patients given the recommended clinical dose together with concomitant immunosuppressive therapy. 
V 39-tedenski raziskavi je bila pri največjem odmerku njihova sistemska izpostavljenost zdravilu (AUC) približno 1.000-krat večja kot pri bolnikih, ki so dobili priporočeni klinični odmerek skupaj s sočasnim zdravljenjem z zdravili za zaviranje imunske odzivnosti.
Of 339 renal transplant patients treated with basiliximab and tested for anti-idiotype antibodies, 4 (1.2%) developed an anti-idiotype antibody response. 
Od 339 bolnikov z ledvičnimi presadki, zdravljenih z baziliksimabom in testiranih na antiidiotipska protitelesa, se je pri 4 bolnikih (1,2 %) razvil odziv antiidiotipskih protiteles.
Simulect powder 
Prašek Simulect
The incidence rates of adverse events and the pattern of adverse events were comparable between the two treatment groups and to be expected for the treatment regimens and the underlying diseases. 
Pogostnost pojavljanja neželenih dogodkov in vzorec neželenih dogodkov sta bila primerljiva med obema obravnavanima skupinama in v skladu s pričakovanji glede na shemo zdravljenja in osnovne bolezni.
No maternal toxicity, embryotoxicity, or teratogenicity was observed in cynomolgous monkeys following injections of up to 5 mg/kg basiliximab administered twice weekly during the organogenesis period. 
Nikakršne toksičnosti za mater ali zarodek ter teratogenosti niso opazili pri opicah cinomolgus po injekcijah do 5 mg/kg baziliksimaba, odmerjenih dvakrat tedensko med obdobjem organogeneze.
The efficacy and safety of Simulect for the prophylaxis of acute rejection in recipients of solid organ allografts other than renal have not been demonstrated. 
Varnost in učinkovitost uporabe zdravila Simulect za profilakso akutne zavrnitve po alogeni presaditvi čvrstega organa, ki ni ledvica, nista bili dokazani.
Usual dose for adults The usual dose for adults is 20 mg in each infusion or injection. 
Običajni odmerek za odrasle Običajni odmerek za odrasle je 20 mg v vsaki infuziji ali injekciji.
The adverse event profile remained comparable between treatment groups. 
Profil neželenih dogodkov je med obema skupinama ostal primerljiv.
The incidence and causes of deaths following dual or triple therapy were similar in basiliximab (2.9%) and placebo groups (2.6%), with the most common cause of deaths in both treatment groups being infections (basiliximab = 1.3%, placebo = 1.4%). 
Incidenca smrtnih izidov in vzrokov smrti po dvotirnem ali tritirnem zdravljenju je bila v skupini z baziliksimabom (2,9 %) in placebom (2,6 %) podobna; najpogostejši vzrok smrti v obeh tretiranih skupinah so bile okužbe (baziliksimab = 1,3 %, placebo = 1,4 %).
The overall incidence of infections was 75.9% in the basiliximab group and 75.6% in the placebo group and the incidence of serious infections was 26.1% and 24.8%, respectively. 
Celotna incidenca okužb je bila 75,9 % v skupini z baziliksimabom in 75,6 % v skupini s placebom; incidenca hudih okužb je bila 26,1 % v skupini z zdravilom Simulect in 24,8 % v skupini s placebom.
The available clinical data on the use of muromonabCD3 in patients previously treated with basiliximab suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations is not precluded. 
Razpoložljivi klinični podatki o uporabi muromonaba-CD3 pri bolnikih, predhodno zdravljenih z baziliksimabom, kažejo, da to ne ovira kasnejše uporabe muromonaba-CD3 ali drugih pripravkov glodalskih protilimfocitnih protiteles.
Transplant patients receiving immunosuppressive regimens involving combinations with or without basiliximab are at increased risk of developing lymphoproliferative disorders (LPDs) (such as lymphoma) and opportunistic infections (such as cytomegalovirus [CMV], BK virus). 
Pri bolnikih s presajenimi organi, ki prejemajo imunosupresivno shemo zdravljenja s kombinacijo z baziliksimabom ali brez njega, je povečana nevarnost nastanka limfoproliferativnih bolezni (LPD), kot je na primer limfom, in oportunističnih okužb, kot je na primer okužba s citomegalovirusom (CMV) ali z virusom BK.
Ask your doctor, nurse or pharmacist for advice before taking any medicine while you are pregnant or breast-feeding. 
Posvetujte se z zdravnikom, medicinsko sestro ali s farmacevtom, preden v nosečnosti ali med dojenjem vzamete katerokoli zdravilo.
These will be given in hospital, around the time of your transplant operation. 
Prejeli boste samo dva odmerka zdravila Simulect in sicer v bolnišnici približno ob času vaše presaditvene operacije.
In a pooled analysis of two five-year open-label extension studies (586 patients total) the combined graft and patient survival rates were not statistically different for the basiliximab and placebo groups. 
V združeni analizi dveh petletnih odprtih podaljšanih raziskav (skupaj 586 bolnikov) se kombinirani pogostnosti preživetja presadka in bolnika v skupini z baziliksimabom in skupini s placebom nista statistično razlikovali.
An overdose of Simulect is not likely to cause side effects straight away, but it may weaken your immune system for longer. 
Če ste dobili večji odmerek zdravila Simulect, kot bi smeli Ni verjetno, da bi prevelik odmerek zdravila Simulect takoj imel stranske učinke, vendar lahko oslabi vaš imunski sistem za dalj časa.
The efficacy of basiliximab in prophylaxis of organ rejection in de novo renal transplantation has been demonstrated in double-blind placebo-controlled studies. 
Učinkovitost baziliksimaba pri preprečevanju zavrnitve organa pri de novo presajeni ledvici je bila prikazana v dvojno slepih raziskavah, v katerih so kontrolne skupine dobivale placebo.
The pharmacokinetics of basiliximab were assessed in 39 paediatric de novo renal transplantation patients. 
Farmakokinetika baziliksimaba je bila ocenjena pri 39 pediatričnih bolnikih z de novo presaditvijo ledvice.
Cytokine release syndrome. 
Sindrom sproščanja citokinov.
Simulect is contraindicated in pregnancy and lactation (see section 4.3). 
Zdravilo Simulect je kontraindicirano med nosečnostjo in dojenjem (glejte poglavje 4.3).
If you have experienced a severe allergic reaction to Simulect or if you had complications after your surgery such as graft loss, the second dose of Simulect should not be given to you. 
Če ste imeli hudo alergijsko reakcijo na zdravilo Simulect ali če je po operaciji prišlo do zapletov, kot je izguba presadka, ne smete prejeti drugega odmerka zdravila Simulect.
In infants and children (age 1-11 years, n=25), the steady-state distribution volume was 4.82.1 l, half-life was 9.54.5 days and clearance was 176 ml/h. 
Pri dojenčkih in otrocih (starost 1-11 let, n = 25) je bil porazdelitveni volumen v stanju ravnovesja 4,8  2,1 l, razpolovni čas je bil 9,5  4,5 dni, očistek pa 17  6 ml/h.
Incidence of malignant neoplasms: The overall incidence of malignancies among all patients in the individual studies was similar between the basiliximab and the comparator treatment groups. 
Incidenca malignih neoplazem: Celotna incidenca malignih bolezni med vsemi bolniki v posameznih raziskavah je bila podobna v skupinah z baziliksimabom in v skupinah s primerjanimi načini zdravljenja.
The second dose should not be given if severe hypersensitivity reactions to Simulect or graft loss occur. 
Drugega odmerka ne smemo dati, če nastopijo hude preobčutljivostne reakcije na zdravilo Simulect ali izguba presadka.
Disposition in adolescents was similar to that in adult renal transplantation patients. 
Porazdelitev pri mladostnikih je bila podobna kot pri odraslih bolnikih po presaditvi ledvice.
Solvent for Simulect Water for injections 
vehikel za zdravilo Simulect voda za injekcije
Basiliximab was used concomitantly with ciclosporin for microemulsion and steroids in an uncontrolled study in 41 paediatric de novo renal transplant recipients. 
Baziliksimab je bil uporabljen skupaj s ciklosporinom v mikroemulziji in s steroidi v nekontrolirani raziskavi pri 41 pediatričnih de novo prejemnikih ledvičnih presadkov.
These concomitant medications include systemic antiviral, antibacterial and antimycotic medications, analgesics, antihypertensive medications such as beta-blocking agents or calcium channel blockers, and diuretics. 
Ta sočasno aplicirana zdravila vključujejo sistemska protivirusna, protibakterijska in protiglivična zdravila, analgetike, antihipertenzivna zdravila, na primer zaviralce adrenergičnih receptorjev beta ali zaviralce kalcijevih kanalčkov, in diuretike.
Basiliximab specifically binds with high affinity (KD-value 0.1 nM) to the CD25 antigen on activated T-lymphocytes expressing the high affinity interleukin-2 receptor (IL2R) and thereby prevents binding of interleukin-2, a critical signal for T-cell proliferation in the cellular immune response involved in allograft rejection. 
Baziliksimab se specifično veže z veliko afiniteto (vrednost KD 0,1 nmol) na antigen CD25 na aktiviranih limfocitih T, z izraženim receptorjem za interlevkin-2 (IL-2R) velike afinitete, in tako prepreči vezavo interlevkina 2, ki je odločilen signal za proliferacijo celic T pri celičnem imunskem odzivu, ki je vpleten v zavrnitev presadka.
Basiliximab does not cause myelosuppression. 
Baziliksimab ne povzroči mielosupresije.
The following adverse reactions have been identified based on post-marketing spontaneous reports and are organised by system organ class. 
Na podlagi postmarketinških spontanih poročil so odkrili naslednje neželene učinke, ki so razvrščeni glede na organski sistem.
The use of basiliximab does not preclude subsequent treatment with murine antilymphocyte antibody preparations. 
Dajanje baziliksimaba ne izključuje poznejšega zdravljenja s pripravki glodalskih protilimfocitnih protiteles.
In children, the most commonly reported side effects were constipation, excessive growth of normal hair, runny or blocked nose, fever, high blood pressure, and various kinds of infections. 
Pri otrocih so najpogosteje poročani neželeni učinki zapeka, čezmerna rast normalnih las in dlak, izcedek iz nosu ali zamašen nos, vročina, zvišan krvni tlak in različne vrste okužb.
Other malignancies were reported among 1.0% (7/701) of patients in the basiliximab group compared with 1.2% (7/595) of placebo patients. 
O drugih malignih boleznih so poročali pri 1,0 % bolnikov (7/701) v skupini z baziliksimabom v primerjavi z 1,2 % bolnikov (7/595) v skupini s placebom.
The use of basiliximab in a triple therapy regimen including azathioprine or mycophenolate mofetil did not increase adverse events or infections in the basiliximab group as compared to placebo (see section 4.8). 
Uporaba baziliksimaba v programu trotirnega zdravljenja skupaj z azatioprinom ali mofetilmikofenolatom ni povečala obsega neželenih dogodkov ali okužb v skupini z baziliksimabom v primerjavi s placebom (glejte poglavje 4.8).
In clinical trials, the incidence of opportunistic infections was similar in patients using immunosuppressive regimens with or without Simulect. 
V kliničnih preskušanjihje bila pogostnost oportunističnih okužb podobna pri bolnikih, ki uporabljali imunosupresivne sheme zdravljenja, ne glede na to, ali je shema vsebovala zdravilo Simulect ali ne.
In vitro studies using human tissues indicate that basiliximab binds only to activated lymphocytes and macrophages/monocytes. 
Raziskave in vitro na človeških tkivih so pokazale, da se baziliksimab veže samo na aktivirane limfocite in makrofage oziroma monocite.
In a pooled analysis of two fiveyear extension studies, the incidence of LPDs and cancer was found to be equal with basiliximab 7% (21/295) and placebo 7% (21/291) (see section 4.4). 
V združeni analizi dveh petletnih podaljšanih raziskav so ugotovili, da je bila pogostnost limfoproliferativnih bolezni in raka enaka pri baziliksimabu (7 % - 21/295) in placebu (7 % - 21/291) (glejte poglavje 4.4).
Basiliximab has been tested in four randomised, double-blind, placebo-controlled studies in renal transplant recipients as an induction agent in combination with the following immunosuppressive regimens: ciclosporin for microemulsion and corticosteroids in two studies (346 and 380 patients), ciclosporin for microemulsion, azathioprine and corticosteroids in one study (340 patients), and ciclosporin for microemulsion, mycophenolate mofetil and corticosteroids in another study (123 patients). 
Baziliksimab je bil kot uvodna učinkovina preizkušen v štirih randomiziranih, dvojno slepih, s placebom kontroliranih raziskavah pri prejemnikih ledvičnih presadkov in sicer v kombinaciji z naslednjimi imunosupresivnimi shemami: ciklosporin v mikroemulziji in kortikosteroidi v dveh raziskavah (346 in 380 bolnikov), ciklosporin v mikroemulziji, azatioprin in kortikosteroidi v eni raziskavi (340 bolnikov) ter ciklosporin v mikroemulziji, mofetilmikofenolat in kortikosteroidi v drugi raziskavi (123 bolnikov).
sodium chloride; sucrose; mannitol (E421); glycine. 
natrijev klorid; saharoza; manitol (E421); glicin.
- The other ingredients are potassium dihydrogen phosphate; disodium phosphate, anhydrous; 
- Druge sestavine zdravila so: kalijev dihidrogenfosfat; natrijev hidrogenfosfat, brezvodni;
Discard the reconstituted solution if not used within 24 hours. 
Če pripravljene raztopine ne porabite v 24 urah, jo zavrzite.
In adolescents (age 12-16 years, n=14), the steady-state distribution volume was 7.85.1 l, half-life was 9.13.9 days and clearance was 3119 ml/h. 
12-16 let, n = 14) je bil porazdelitveni volumen v stanju ravnovesja 7,8  5,1 l, razpolovni čas je bil 9,1  3,9 dni, očistek pa 31  19 ml/h.
Overall, lymphoma/lymphoproliferative disease occurred in 0.1% (1/701) of patients in the basiliximab group compared with 0.3% (2/595) of patients receiving placebo, both in combination with dual and triple immunosuppressive therapy. 
Limfomi oziroma limfoproliferativne bolezni so se pojavili pri 0,1 % bolnikov (1/701) v skupini z baziliksimabom in pri 0,3 % bolnikov (2/595), ki so prejemali placebo, tako v kombinaciji z dvotirnim kot s trotirnim imunosupresivnim zdravljenjem.
The overall incidence of treatment-related adverse events among all patients in the individual studies was not significantly different between the basiliximab (7.1% - 40%) and the placebo (7.6% - 39%) treatment groups. 
Celotna incidenca neželenih učinkov v zvezi z zdravljenjem se med vsemi bolniki v posameznih raziskavah ni bistveno razlikovala med skupino, zdravljeno z baziliksimabom (7,1 % - 40 %), in skupino, ki je dobivala placebo
Because basiliximab is an immunoglobulin, no metabolic drug-drug interactions are to be expected. 
Ker je baziliksimab imunoglobulin, presnovne interakcije z drugimi zdravili niso pričakovane.
There was no significant difference between basiliximab and placebo-treated patients in graft survival after 6 and 12 months (at 12 months 32 graft losses on basiliximab (9%) and 37 graft losses on placebo (10%)). 
Ni bilo bistvene razlike v preživetju presadka po 6 in po 12 mesecih med skupino bolnikov, ki je dobivala baziliksimab, in skupino, ki je dobivala placebo (po 12 mesecih je bilo pri baziliksimabu 32 izgubljenih presadkov (9 %) in pri placebu 37 izgubljenih presadkov (10 %)).
In a pooled analysis of two five-year extension studies the incidence and cause of death remained similar in both treatment groups, (basiliximab 15%, placebo 11%), the primary cause of death being cardiac-related disorders such as cardiac failure and myocardial infarction (basiliximab 5%, placebo 4%). 
V združeni analizi dveh petletnih podaljšanih raziskav so pogostnost in vzroki smrti ostali podobni v obeh tretiranih skupinah (baziliksimab 15 %, placebo 11 %), primarni vzrok smrti pa so bile bolezni, povezane s srcem, kot sta popuščanje srca in miokardni infarkt (baziliksimab 5 %, placebo 4 %).
In addition to ciclosporin for microemulsion, steroids, azathioprine and mycophenolate mofetil, other concomitant medications routinely administered in organ transplantation have been administered in clinical trials without any incremental adverse reactions. 
Poleg ciklosporina v mikroemulziji, steroidov, azatioprina in mofetilmikofenolata so v kliničnih raziskavah sočasno z zdravilom Simulect dajali druga zdravila, ki se običajno dajejo pri presaditvah organov, ne da bi se obseg neželenih reakcij kakorkoli povečal.
Graft loss occurred in 6% of basiliximab-treated and 10% of placebo-treated patients by 6 months. 
Po 6 mesecih je do izgube presadka prišlo pri 6 % bolnikov, ki so prejemali baziliksimab, in pri 10 % bolnikov, ki so prejemali placebo.
Reconstituted products should be inspected visually for particulate matter prior to administration. 
Pripravljeno zdravilo je potrebno pred uporabo vizualno pregledati glede vsebnosti delcev.
The use of live attenuated vaccines should therefore be avoided in patients treated with Simulect. 
Pri bolnikih, ki prejemajo zdravilo Simulect, se je torej treba izogibati uporabi živih atenuiranih cepiv.
Infusion bag - Baxter minibag NaCl 0.9% 
Preverili so združljivost z naslednjimi infuzijskimi kompleti: Infuzijska vrečka - Baxter minibag NaCl 0,9 %
Usual dose for children and adolescents (aged 1 to 17 years) - For children and adolescents who weigh less than 35 kg, the dose of Simulect given in each infusion or injection is 10 mg. - For children and adolescents who weigh 35 kg or more, the dose of Simulect given in each infusion or injection is 20 mg. 
Običajni odmerek za otroke in mladostnike (stare od 1 do 17 let) - Za otroke in mladostnike, ki tehtajo manj od 35 kg, je odmerek zdravila Simulect v vsaki infuziji ali injekciji 10 mg. - Za otroke in mladostnike, ki tehtajo 35 kg ali več, je odmerek zdravila Simulect v vsaki infuziji ali injekciji 20 mg.
Three clinical trials have investigated basiliximab use in combination with a triple therapy regimen which included either azathioprine or mycophenolate mofetil. 
V treh kliničnih raziskavah so raziskovali uporabo baziliksimaba v kombinaciji s programom trotirnega režima zdravljenja, ki je obsegal bodisi azatioprin bodisi mofetilmikofenolat.
Usual dose for children and adolescents (aged 1 to 17 years) - For children and adolescents who weigh 35 kg or more, the dose of Simulect given in each infusion or injection is 20 mg. - For children and adolescents who weigh less than 35 kg, the dose of Simulect given in each infusion or injection is 10 mg. 
Običajni odmerek za otroke in mladostnike (stare od 1 do 17 let) - Za otroke in mladostnike, ki tehtajo 35 kg ali več, je odmerek zdravila Simulect v vsaki infuziji ali injekciji 20 mg. - Za otroke in mladostnike, ki tehtajo manj od 35 kg, je odmerek zdravila Simulect v vsaki infuziji ali injekciji 10 mg.
In a pooled analysis of two five-year extension studies, no differences were found in the incidence of malignancies and LPDs between immunosuppressive regimens with or without combination of basiliximab (see section 4.8). 
V združeni analizi dveh petletnih podaljšanih raziskav niso našli nobenih razlik v pogostnosti malignih in limfoproliferativnih bolezni med imunosupresivnimi shemami s kombinacijo z baziliksimabom v primerjavi s kombinacijami brez njega (glejte poglavje 4.8).
When borderline rejections were included in the primary efficacy endpoint, the rates were 26.0% and 23.9% respectively, with no statistically significant difference between the basiliximaband placebo-treated groups (HR: 1.04, 90% CI: [0.64; 1.68]). 
Če so med dogodke za primarni cilj opazovanja šteli tudi mejne zavrnitve, sta ustrezna deleža znašala 26,0 % in 23,9 %, brez statistično značilne razlike med skupinama, ki sta prejemali baziliksimab oziroma placebo (razmerje tveganj: 1,04; 90-odstotni IZ: [0,64; 1,68]).